Most American investors are familiar with large European drug companies like Sanofi and Novartis (NVS), but the mid-cap drugmakers like Ipsen (OTCPK:IPSEY)
don't get as much attention. That's unfortunate, as Ipsen is one of
several high-quality smaller European pharmaceutical companies.
Ipsen
shares don't look significantly underpriced today, but there could some
developments that could drive shares higher. Phase III data on
tasquinimod could make this drug a viable alternative in the crowded
prostate cancer space, and Ipsen may be on the prowl for licensing or
acquisition opportunities to take advantage of a new U.S. oncology sales
infrastructure. I'd more interested in these shares closer to EUR 30,
but they look like a decent enough hold at today's level.
Read more here:
Ipsen In Good Shape
No comments:
Post a Comment